Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AM...(ed Harry P. Erba MD Ph.D. University ofM...),Health

Date:6/2/2008

ed Harry P. Erba, MD, Ph.D., University of Michigan, one of the co-principal investigators for this study. "This study helps to define a new approach to treatment for patients unlikely to benefit from conventional 7+3 induction chemotherapy and provides support for the importance of assessing cytogenetics prior to induction treatment."

"The positive results seen in this study provide a compelling case for a novel, effective, therapeutic option for older adult patients with AML who have multiple unfavorable prognostic factors," added Hagop Kantarjian, M.D. MD Anderson Cancer Center and the other co-principal investigator for the CLASSIC II study. "In our published research from MD Anderson, older AML patients with one to three unfavorable prognostic factors are at risk of lower complete remission rates and higher 60-day mortality. We look forward to analyzing the final independently-assessed study results, particularly the remission duration data, for this very difficult-to-treat population."

In addition to presentation at ASCO, a podium appearance of the preliminary CLASSIC-II data also will be delivered by Dr. Erba at the upcoming European Hematology Association meeting in Copenhagen, Denmark on Sunday, June 15.

Study Design

Patients in the CLASSIC-II study must have previously untreated AML, be 60 years or older and be unlikely to benefit from conventional induction chemotherapy based on the presence of at least one of the following adverse prognostic factors: age greater than or equal to 70, pre-existing hematological disorder such as myelodysplastic syndrome (MDS), poor health performance, or intermediate or unfavorable cytogenetics. Patients also had to be previously untreated and unlikely to benefit from conventional induction chemotherapy (7+3 anthracycline plus cytarabine) based on the presence of at least one of these poor prognostic factors at baseline.

Patients received an induction cycle of intravenous clofarabine admin
'/>"/>

SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds